Ovarian cancers in women with BRCA1/2
germline mutations are characterized by an
improved response to platinum-based
chemotherapy at first and subsequent relapses
and better outcomes (PFS, OS)
Defining BRCAness Phenotype
Tan JCO 2008
Tan D JCO 2008; Fong FC JCO 2010; Audeh MW Lancet 2010; Ledermann J Lancet 2014; Fong FC NEJM 2009